EP0574477A1 - Produits pharmaceutiques - Google Patents

Produits pharmaceutiques

Info

Publication number
EP0574477A1
EP0574477A1 EP92906079A EP92906079A EP0574477A1 EP 0574477 A1 EP0574477 A1 EP 0574477A1 EP 92906079 A EP92906079 A EP 92906079A EP 92906079 A EP92906079 A EP 92906079A EP 0574477 A1 EP0574477 A1 EP 0574477A1
Authority
EP
European Patent Office
Prior art keywords
methyl
acetyl
alkyl
formula
pyrrolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92906079A
Other languages
German (de)
English (en)
Inventor
Giuseppe Dr Lo Zambeletti S.P.A. Giardina
Geoffrey Douglas Dr Lo Zambeletti S.P.A. Clarke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline SpA
Original Assignee
Smithkline Beecham Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Farmaceutici SpA filed Critical Smithkline Beecham Farmaceutici SpA
Publication of EP0574477A1 publication Critical patent/EP0574477A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Definitions

  • the present invention relates to the use of certain compounds for the manufacture of medicaments for the treatment of cerebral ischaemia; to a method of treatment of cerebral ischaemia; and to pharmaceutical compositions for the treatment of cerebral ischaemia.
  • EP-A-370732 and EP-A-361791 (both Dr. Lo. Z combitti S.p.a.) describe classes of azacyclic and heterocyclic derivatives which exhibit kappa receptor agonism and are of potential therapeutic utility as analgesics.
  • formula (la) being:
  • RCO is an acyl group in which the group R contains a substituted or unsubstituted carbocyclic aromatic or heterocyclic aromatic ring;
  • R 1 and R 2 are independently hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 3-6 cycloalkyl or C 4-12 eycloalkylalkyl groups, or together form a C 2-8 branched or linear polymethylene or C 2-6 alkenylene group, optionally substituted with a hetero-atom,
  • R 3 is hydrogen , C 1-6 alkyl, preferably methyl or ethyl, or phenyl, or R 3 together with R 1 form a -(CH 2 ) 3 - or -(CH 2 ) 4 - group;
  • R 4 and R 5 are independently hydrogen, hydroxyl, halogen, preferably fluorine, C 1-6 alkyl, preferably methyl or ethyl, or aryl, preferably phenyl, provided both R 4 and R 5 are not simultaneously hydrogen; and p is an integer from 1 to 4, preferably 2;
  • R x is the remainder of a heterocyclic group, or an optionally substituted phenyl group
  • R a and R b are independently hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 3-6 cycloalkyl or C 4-12 cycloalkylalkyl groups, or together form a C 2-8 branched or linear polymethylene or C 2-6 alkenylene group, optionally substituted with a hetero-atom;
  • R c is hydrogen , C 1-6 alkyl, preferably methyl or ethyl, or phenyl, or R c together with R a form a -(CH 2 ) 3 - or -(CE 2 ) 4 - group;
  • R d and R e which may be located on the same or different carbon atoms, are independently hydrogen, C 1-6 alkyl, preferably methyl or ethyl, or phenyl; m is 1, 2 or 3, preferably 2;
  • R f is hydrogen or C 1-6 alkyl, such as methyl or ethyl; n is O, 1 or 2 preferably 1;
  • each of R g and R h is C 1-6 alkyl, or
  • R g and R h are linked together and Rg represents -(Z) p - where p is 0 or 1 and Z is O, S or NR Z where R z is hydrogen or C 1-6 alkyl,
  • R h represents -(CH 2 ) q - where q is an integer of from 1 to 4, preferably 2 or 3.
  • R 4 and R 5 may be located on the same or different carbon atoms of the azacyclic nucleus.
  • the term 'carbocyclic aromatic group' includes single or fused rings, having 6 to 12 ring carbon atoms
  • the term 'heterocyclic aromatic group includes single or fused rings having 5 to 12 ring atoms, comprising up to four hetero-atoms in the or each ring, selected from oxygen, nitrogen and sulphur.
  • one or both rings may be aromatic in character.
  • one of the rings is aromatic and the other is non-aromatic.
  • the C 1-6 alkyl groups may be either straight or branched chain and examples are methyl, ethyl, propyl, n-butyl, n-pentyl or n-hexyl, preferably methyl.
  • Examples of C 2-6 alkenyl groups are 1- and 2-propenyl; an example of a C 3-6 cycloalkyl group is cyclopropyl, and an example of a C 4-12
  • cycloalkylalkyl group is cyclopropyl methyl.
  • R 1 and R 2 together form a linear or branched polymethylene group, examples are propylene, butylene, pentylene or hexylene, preferably butylene or 1-methyl-butylene.
  • hetero-atoms are oxygen and sulphur, particularly oxygen, and a suitable hetero-atom substituted polymethylene group is -CH 2 CH 2 OCH 2 CH 2 -.
  • the group R in formula (la) preferably has the formula (III):
  • n 0, 1 or 2;
  • n 0, 1 or 2;
  • n' is 0, 1 or 2, provided m + m' ⁇ 2
  • X is a direct bond, or O, S or NR 8 in which R 8 is hydrogen or C 1-6 alkyl,
  • Ar is a substituted or unsubstituted carbocyclic or heterocyclic group
  • each of R 6 and R 6 a is C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 2-6 haloalkenyl, C 2-6 haloalkynyl, optionally substituted phenyl, optionally substituted phenyl C 1-6 alkyl, hydroxy, C 1-6 alkoxy, thiol, C 1-6 alkylthio, C 1-6 haloalkoxy, C 1-6 haloalkylthio, halogen, NO 2 , CN, CF 3 , -OCF 3 , -OCHF 2 , -OCF 2 CF 2 H, -OCCl 2 CF 3 , -COOR 9 ,
  • each of R 9 to R 15 is independently hydrogen, C 1-6 alkyl, optionally substituted phenyl or optionally substituted phenyl C 1-6 alkyl;
  • R 6 's form a C 3-6 polymethylene group
  • R 7 is hydrogen or C 1-6 alkyl, such as methyl or ethyl.
  • Preferred halogens are F, Cl and Br.
  • R 6 's When two R 6 's are linked they preferably form a fused cyclopentyl or cyclohexyl ring.
  • Ar is phenyl and R 6 or R 6 a is preferably in the meta and/or para position.
  • R 6 or R 6 a is bromine, chlorine, or CF 3 , particularly in the meta- or para- position.
  • X is typically oxygen or a direct bond, and n is typically 0 or 1.
  • a further preferred group R has the formula (IV)
  • each of R x and R y is C 1-6 alkyl, or
  • R x and R y are linked together and R x represents -(Z) m - where m is 0 or 1 and Z is O, S or NR Z where R z is hydrogen or C 1-6 alkyl,
  • R y represents -(CH 2 ) q - where q is an integer of from 1 to 4, preferably 2 or 3.
  • a preferred sub-group of formula (IV) is a group of formula (V)
  • q is 2 when Z is oxygen and m is 1, and q is 3 when m is 0.
  • a further preferred sub-group of formula (IV) is the group of formula (VI)
  • each of R x and R y is C 1-6 alkyl, preferably methyl, and the position of -CH 2 - is as defined in formula (IV)
  • substituents are one or more of C 1-6 alkyl, preferably methyl, halogen, hydroxy, C 1-6 alkoxy, thiol or C 1-6 alkyl thio.
  • R x represents unsubstituted phenyl.
  • R x When R x forms a heterocyclic group, it may be a single or fused ring group, preferably having aromatic character, containing from 5 to 12 ring atoms and comprising up to four hetero-atoms in the or each ring selected from oxygen, nitrogen and sulphur.
  • R x forms a fused two ring system
  • one or both rings may be aromatic in character.
  • one of the rings is aromatic and the other is non-aromatic.
  • R x is a single ring heterocyclic group
  • examples are thienyl, furyl, pyrryl, imidazolyl, pyrazolyl, thiazolyl and pyridyl
  • examples are benzofuranyl, benzo thienyl, indolyl and quinolyl.
  • a preferred sub-group of compounds of formula (lb) is a group of compounds of formula (VII)
  • q is 2 when Z is oxygen and p is 1, and q is 3 when p is 0.
  • q is 2 when Z is oxygen and p is 1, and q is 3 when p is 0.
  • a irther preferred sub-group of compounds of formula (lb) is the group of compounds of formula (VIII)
  • each of R g and R h is C 1-6 alkyl, preferably methyl
  • the position of -CH 2 - is as defined in formula (lb)
  • the C 1-6 alkyl groups mentioned above may be either straight or branched chain and examples are methyl, ethyl, propyl, n-butyl, n-pentyl or n-hexyl, preferably methyl.
  • Examples of C 2-6 alkenyl groups are 1- and 2-propenyl; an example of a C 3-6 cycloalkyl group is cyclopropyl, and an example of a C 4-12
  • cycloalkylalkyl group is cyclopropyl methyl.
  • R a and R b together form a linear or branched polymethylene group
  • examples are propylene, butylene, pentylene or hexylene, preferably butylene or 1-methyl-butylene.
  • hetero-atoms are oxygen and sulphur, particularly oxygen, and a suitable hetero-atom substituted polymethylene group is -CH 2 CH 2 OCH 2 CH 2 -.
  • a particularly preferred group of compounds of formula (lb) are those in which R x represents phenyl or mono- or di- hydroxy substituted phenyl, or represents thieno.
  • compositions for use in the treatment of cerebral ischaemia in mammals which comprises a compound of formula (la) or (lb) (as hereinbefore defined) or a pharmaceutically acceptable salt or solvate thereof,
  • the invention further provides a method for the treatment and/or prophylaxis of cerebral ischaemia in mammals, particularly humans, which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective amount of the Compound.
  • the Compound is in pharmaceutically acceptable or substantially pure form.
  • pharmaceutically acceptable form is meant, inter aliaj of a pharmaceutically acceptable level of purity excluding normal
  • a substantially pure form will generally contain at least 50% (excluding normal pharmaceutical additives), preferably 75%, more preferably 90% and still more preferably 95% of the Compound.
  • One preferred pharmaceutically acceptable form is the crystalline form, including such form in a pharmaceutical composition.
  • the additional ionic and solvent moieties must also be non-toxic.
  • the Compound in the form of a pharmaceutically acceptable salt include the acid addition salts with the conventional pharmaceutical acids, for example, maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric, succinic, benzoic, ascorbic and methanesulphonic.
  • An example of the Compound in the form of a pharmaceutically acceptable solvate includes the hydrate.
  • the Compounds have at least two asymmetric centres and therefore exist in more than one stereoisomeric form.
  • the invention extends to the use of all such forms and to mixtures thereof, including racemates.
  • Medicaments and compositions containing the Compounds may be prepared by admixture of a Compound with an appropriate carrier, which may contain a diluent, binder, filler, disintegrant, flavouring agent, colouring agent, lubricant or preservative in conventional manner.
  • an appropriate carrier which may contain a diluent, binder, filler, disintegrant, flavouring agent, colouring agent, lubricant or preservative in conventional manner.
  • a medicament or pharmaceutical composition of the invention is in unit dosage form and in a form adapted for use in the medical or veterinarial fields.
  • preparations may be in a pack form accompanied by written or printed instructions for use as an agent for treating cerebral ischaemia.
  • the suitable dosage range for a Compound depends on the Compound to be employed and on the condition of the patient. It will also depend, inter alia, upon the relation of potency to absorbability and the frequency and route of administration.
  • the Compound may be formulated for administration by any route, and is preferably in unit dosage form or in a form that a human patient may administer to himself in a single dosage.
  • the composition is suitable for oral, rectal, topical, parenteral, intravenous or
  • Preparations may be designed to give slow release of the active ingredient.
  • Compositions may, for example, be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, reconstitutable powders, or liquid preparations, for example solutions or suspensions, or
  • compositions for example those suitable for oral administration, may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrroiidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate;
  • binding agents for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrroiidone
  • fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine
  • tabletting lubricants for example magnesium stearate
  • disintegrants for example starch, polyvinylpyrroiidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable setting agents such as sodium lauryl sulphate.
  • Solid compositions may be obtained by conventional methods of blending, filling, tabletting or the like Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers.
  • compositions may be used, examples being magnesium stearate, starch, glucose, lactose, sucrose, rice flour and chalk. Tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.
  • the composition may also be in the form of an ingestible capsule, for example of gelatin containing the compound, if desired with a carrier or other excipients.
  • compositions for oral administration as liquids may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid compositions may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; aqueous or non-aqueous vehicles, which include edible oils, for example almond oil, fractionated coconut oil, oily esters, for example esters of glycerine, or propylene glycol, or ethyl alcohol, glycerine, water or normal saline; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired
  • compositions may also be administered by a non-oral route.
  • the compositions may be formulated, for example for rectal administration as a suppository.
  • They may also be formulated for presentation in an injectable form in an aqueous or non-aqueous solution, suspension or emulsion in a
  • liquid e.g. sterile pyrogen-free water or a parenterally acceptable oil or a mixture of liquids.
  • the liquid may contain bacteriostatic agents, anti-oxidants or other preservatives, buffers or solutes to render the solution isotonic with the blood, thickening agents, suspending agents or other pharmaceutically acceptable additives.
  • Such forms will be presented in unit dose form such as ampoules or disposable injection devices or in multi- dose forms such as a bottle from which the appropriate dose may be withdrawn or a solid form or concentrate which can be used to prepare an injectable formulation.
  • the effective dose of Compound depends on the particular Compound employed, the condition of the patient and on the frequency and route of administration.
  • a unit dose will generally contain from 20 to 1000 mg and preferably will contain from 30 to 500 mg, in particular 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg.
  • the composition may be administered once or more times a day for example 2, 3 or 4 times daily, and the total daily dose for a 70 kg adult will normally be in the range 100 to 3000 mg.
  • the unit dose will contain from 2 to 20mg of active ingredient and be administered in multiples, if desired, to give the preceding daily dose.
  • the activity of the Compounds in treating cerebral ischaemia may be determined using the gerbil model of ischaemic stroke, as described in P. Lysko et al Stroke, 23(3), 1992.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

On décrit des dérivés azacycliques et hétérocycliques présentant une activité agoniste kappa et utiles pour le traitement de l'ischémie cérébrale.
EP92906079A 1991-03-05 1992-03-04 Produits pharmaceutiques Withdrawn EP0574477A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9104656 1991-03-05
GB919104656A GB9104656D0 (en) 1991-03-05 1991-03-05 Pharmaceuticals

Publications (1)

Publication Number Publication Date
EP0574477A1 true EP0574477A1 (fr) 1993-12-22

Family

ID=10691041

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92906079A Withdrawn EP0574477A1 (fr) 1991-03-05 1992-03-04 Produits pharmaceutiques

Country Status (8)

Country Link
EP (1) EP0574477A1 (fr)
CA (1) CA2105589A1 (fr)
GB (1) GB9104656D0 (fr)
IE (1) IE920679A1 (fr)
MX (1) MX9200948A (fr)
PT (1) PT100188A (fr)
WO (1) WO1992015304A2 (fr)
ZA (1) ZA921575B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8926560D0 (en) * 1989-11-24 1990-01-17 Zambeletti Spa L Pharmaceuticals
US5428042A (en) * 1990-04-28 1995-06-27 Dr Lo Zambeletti S.P.A. 1-(2H-1-oxo-3,4-dihydronaphtyl-6-yl)-acetyl-piperidines as kappa agonists
EP1727788B1 (fr) 2004-03-12 2010-07-28 Eli Lilly And Company Antagonistes de recepteur opioide
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
US7615556B2 (en) 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
TWI433838B (zh) 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
US8598164B2 (en) 2010-05-06 2013-12-03 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
KR101923367B1 (ko) 2011-02-02 2018-12-04 버텍스 파마슈티칼스 인코포레이티드 이온 채널의 조절제로서의 피롤로피라진―스피로사이클릭 피페리딘 아미드
MX2013009393A (es) 2011-02-18 2013-08-29 Vertex Pharma Piperidinamidas cromano-espirociclicas como moduladores de canales de iones.
CN103517910B (zh) 2011-03-14 2016-12-14 沃泰克斯药物股份有限公司 作为离子通道调节剂的吗啉-螺环哌啶酰胺

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330467A1 (fr) * 1988-02-23 1989-08-30 Glaxo Group Limited Composés hétérocycliques
JPH01308229A (ja) * 1988-02-23 1989-12-12 Glaxo Group Ltd 複素環誘導体
GB8804104D0 (en) * 1988-02-23 1988-03-23 Glaxo Group Ltd Chemical compounds
GB8813714D0 (en) * 1988-06-09 1988-07-13 Glaxo Group Ltd Chemical compounds
EP0361791B1 (fr) * 1988-09-26 1995-11-08 Smithkline Beecham Farmaceutici S.p.A. Composés azacycliques, utiles commes médicaments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9215304A2 *

Also Published As

Publication number Publication date
WO1992015304A3 (fr) 1993-06-24
MX9200948A (es) 1992-11-01
PT100188A (pt) 1993-05-31
WO1992015304A2 (fr) 1992-09-17
IE920679A1 (en) 1992-09-09
GB9104656D0 (en) 1991-04-17
ZA921575B (en) 1992-12-30
CA2105589A1 (fr) 1992-09-06

Similar Documents

Publication Publication Date Title
WO1992018115A1 (fr) Utilisation de composes heterocycliques pour le traitement de douleurs inflammatoires
US5366981A (en) N-acyl-substituted azacyclic compounds, processes for their preparaion, and their use as pharmaceuticals
EP0574477A1 (fr) Produits pharmaceutiques
SG183853A1 (en) Modulators of hec1 activity and methods therefor
CA2373073A1 (fr) Composes cycliques et leurs utilisations
JPH02184674A (ja) 新規化合物、その製法及びそれを含む医薬組成物
IE914069A1 (en) Treatment method
EP1429771B1 (fr) Composes bicycliques servant d'inhibiteurs de chimiokine se fixant a l'us28
US6121291A (en) Paroxetine in the treatment of depression associated with withdrawal from heroin abuse and post-traumatic stress disorder
US5254564A (en) Substituted isoquinoline compounds, pharmaceutical composition and method of use in treating pain in mammals
JPH09501405A (ja) 抗不整脈用ｎ−置換３−ベンズアゼピンまたはイソキノリン
US5087630A (en) Method for the treatment of a hyponatremic disease
WO1990007502A1 (fr) Composes de decahydroisoquinoline
US6372763B1 (en) Treatment and prevention of cardiac disorders using selective serotonin re-uptake inhibitors (SSRI)
EP0773217A1 (fr) Dérivés de benzothiophènes pour le traitement de tumeurs résistantes
CN109415371B (zh) 一种2-酰氨基噻唑衍生物及其制备方法与用途
IE60299B1 (en) Use of quinoline derivatives in the manufacture of medicaments for the treatment of cerebrovascular disorders and cerebral senility
JP2003511438A (ja) 水和ｎ−［３−［［２−（３，４−ジメトキシフェニル）エチル］アミノ］プロピル］−４−ニトロベンズアミド塩酸塩およびその医薬組成物中における使用
CA2328896A1 (fr) Traitement de trouble anxieux generalise avec de la paroxetine
JP2003511437A (ja) Ｎ−［３−［［２−（３，４−ジメトキシフェニル）エチル］アミノ］プロピル］−４−ニトロベンズアミド塩酸塩の多型相
ITMI961861A1 (it) Derivati tetraciclici spiro-condensati
ITMI960114A1 (it) Uso di derivati di idroisochinolina
WO1992008451A1 (fr) Utilisation de nabumetone pour le traitement de douleurs associees au cancer
HK40004403A (zh) 一种新型2-酰氨基噻唑衍生物及其制备方法与用途
WO1992008452A1 (fr) Utilisation de nabumetone pour le traitement de syndromes de douleurs myofasciales

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930812

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19931215

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19940426